Ancino launches generic Exelon patch
AESCH, Switzerland — Ancino this week launched its rivastigmine patch, a generic version of the Exelon patch. The transdermal treatment is intended for mild to moderate dementia associated with Alzheimer’s disease, and is available in 4.6-mg 24-hour strength, 9.5-mg 24-hour strength and 13.3-mg 24-hour strength.
Acino’s rivastigmine patch will be marketed by Alvogen. This is the first of a series of products Acino plans to launch in the U.S., building on its patch business in Europe
Pfizer completes Hospira acquisition
NEW YORK — Pfizer this week announced that it had completed its acquisition of injectable and infusion drug maker Hospira. Pfizer said that the transaction has strengthened the company’s branded and generics portfolio, particularly when it comes to biosimilars, the market for which is expected to hit $20 billion in 2020, and the first of which was launched in the U.S. on Thursday.
“Together, we are … a leading global biosimilars company with a robust pipeline, best-in-class development capabilities and extensive real-world commercialization experience,” John Young, group president global established pharmaceutical business, said. “By increasing the number and availability of high-quality generic injectable drugs and biosimilars that we offer our customers, we are strengthening our commitment to improving the health and quality of life of patients around the world with high quality medicines across key therapeutic areas.”
The company expects the transaction to boost earnings per share by about $0.10 to $0.12 per share in the year after closing, and will adjust its 2015 guidance to incorporate Hospira in the coming weeks.
Lupin launches Cymbalta generic
BALTIMORE — Lupin Pharmaceuticals on Thursday announced the launch of its duloxetine delayed-release, a generic version of Cymbalta. The drug is available in 20-, 30-, 40- and 60-mg. The company said that its 40-mg strength is among the first generic duloxetine in that strength.
Duloxetine is meant to treat patients with major depressive disorder, generalized anxiety disorder, chronic musculoskeletal pain and diabetic peripheral neuropathic pain.